Exhibit 99.2

Consent of Lucid Capital Markets, LLC

May 13, 2024

Board of Directors

Kintara Therapeutics, Inc.

9920 Pacific Heights Blvd, Suite 150

San Diego, CA 92121

Re: Registration Statement on Form S-4 of Kintara Therapeutics, Inc.

Members of the Board:

We hereby consent to the inclusion of our opinion letter, dated April 2, 2024, to the Board of Directors of Kintara Therapeutics, Inc. (“Kintara”) as Annex B to, and to the reference thereto under the headings “Prospectus Summary — Opinion of Kintara’s Financial Advisor,” “The Merger — The Background of the Merger,” “The Merger — Kintara’s Reasons for the Merger,” and “The Merger — Opinion of Kintara’s Financial Advisor” in the proxy statement/prospectus relating to the proposed merger involving Kintara and TuHURA Biosciences, Inc. (“TuHURA”), which such proxy statement/prospectus forms a part of Kintara and TuHURA’s Registration Statement on Form S-4 (the “Registration Statement”) to be filed on the date hereof, which this consent is filed as an exhibit thereto. In giving the foregoing consent, we do not admit (1) that we come within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended (the “Securities Act”), or the rules and regulations of the Securities and Exchange Commission (the “Commission”) promulgated thereunder, or (2) that we are experts with respect to any part of the Registration Statement within the meaning of the term “experts” as used in the Securities Act and the rules and regulations of the Commission promulgated thereunder.

Very truly yours,

/s/ Lucid Capital Markets

LUCID CAPITAL MARKETS, LLC

LUCID CAPITAL MARKETS, LLC

570 Lexington Ave, 40th Floor

New York NY 10022